11:13a | Goldman Sachs Adjusts BioNTech's Price Target to $206 from $255, Keeps Neutral Rating | MT |
05/23 | Top Midday Gainers | MT |
05/23 | Catalyst Biosciences Stock Surges After Vertex Pharmaceuticals Buys Catalyst's Compleme.. | MT |
05/23 | SVB Securities Initiates Regeneron Pharmaceuticals at Outperform with $738 Price Target | MT |
05/23 | Catalyst Biosciences Shares Soar After Complement Portfolio Sale | DJ |
05/23 | What you need to know about the coronavirus right now | RE |
05/23 | Pfizer, BioNTech Say Third Dose of COVID-19 Vaccine About 80% Effective in Children Age.. | MT |
05/23 | Pfizer, BioNTech Publish Data Supporting COVID-19 Vaccine Efficacy In Children Aged Six.. | MT |
05/23 | SVB Securities Initiates Gilead Sciences at Market Perform With $68 Price Target | MT |
05/23 | SVB Securities Initiates Regeneron Pharmaceuticals at Outperform With $738 Price Target | MT |
05/23 | SVB Securities Initiates Vertex Pharmaceuticals at Market Perform With $265 Price Targe.. | MT |
05/23 | ANALYST RECOMMANDATIONS : AbbVie, Amgen, Caterpillar, HP, Nike... | |
05/23 | Regeneron's Phase 3 Trial Data Shows Positive Results for Potential Treatment of Rare H.. | MT |
05/23 | VERTEX PHARMACEUTICALS INCORPORATED : VRTX) acquired Complement Portfolio of Catalyst Bio.. | CI |
05/20 | Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis | MT |
05/20 | Sanofi's Dupixent wins U.S. approval for bigger use | RE |
05/20 | FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment | DJ |
05/20 | EU Member States Seek Changes To Supply Contracts For COVID-19 Jabs Amid Declining Dema.. | MT |
05/19 | US Health Agency Approves Pfizer-BioNTech's COVID-19 Booster Jab For Children | MT |
05/19 | EU health regulator backs using AstraZeneca COVID shot as booster | RE |
05/19 | European ADRs Move Higher in Thursday Trading | MT |
05/19 | Junshi's COVID-19 Drug Candidate Shows Positive Results in Small Trial; Shares Jump Nea.. | MT |
05/18 | Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director | CI |
05/18 | China Junshi's potential COVID drug shows promise in small trial | RE |
05/17 | Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US | MT |
05/17 | UBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating | MT |
05/17 | Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children | MT |
05/17 | Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi.. | MT |
05/17 | FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11 | DJ |
05/17 | PRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech.. | DJ |
05/17 | Vertex Pharmaceuticals Pledges $50 Million to Health Equity | MT |
05/17 | Vertex Pharmaceuticals Incorporated Announces Further Expansion in the Boston Seaport A.. | CI |
05/17 | ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone... | |
05/17 | Piper Sandler Adjusts Gilead Sciences' Price Target to $69 From $73, Maintains Neutral .. | MT |
05/17 | WuXi Apptec Eyes Issue of Over 78 Million Shares in Hong Kong Under Mandate | MT |
05/16 | Gilead Sciences Says FDA Lifts Hold on Investigational Lenacapavir to Treat HIV | MT |
05/16 | U.S. Food and Drug Administration Lifts Clinical Hold on Investigational Lenacapavir fo.. | CI |
05/16 | Gilead Sciences Says FDA Lifts Clinical Hold On Injectable Lenacapavir | DJ |
05/16 | European ADRs Move Higher in Monday Trading | MT |
05/15 | Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU | MT |
05/13 | UBS Adjusts Gilead Sciences Price Target to $64 From $65, Maintains Neutral Rating | MT |
05/11 | New class of cancer drugs down, not out, after Roche trial setback - analysts | RE |
05/11 | Pfizer's $11.6 billion Biohaven buy could spark more biotech deals | RE |
05/11 | European ADRs Move Sharply Higher in Wednesday Trading | MT |
05/11 | BIONTECH : Goldman Sachs sticks Neutral | MD |
05/10 | TRANSCRIPT : Gilead Sciences, Inc. Presents at Bank of America 2022 Healthcare Conference,.. | CI |
05/10 | TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C.. | CI |
05/10 | Morgan Stanley Lowers BioNTech SE's Price Target to $195 From $197, Equalweight Rating .. | MT |
05/10 | What you need to know about the coronavirus right now | RE |
05/09 | BIONTECH : JP Morgan reiterates its Neutral rating | MD |